Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "approval"

2608 News Found

Eugia Pharma receives USFDA Approval for Icatibant Injection
Drug Approval | August 16, 2023

Eugia Pharma receives USFDA Approval for Icatibant Injection

This is the 166th ANDA out of Eugia Pharma Speciality Group facilities


Lupin receives USFDA approval for fluocinolone acetonide body oil
Drug Approval | August 09, 2023

Lupin receives USFDA approval for fluocinolone acetonide body oil

Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023


Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation
Drug Approval | August 03, 2023

Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation

Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.


Lupin receives approval from US FDA for Turqoz
Drug Approval | August 02, 2023

Lupin receives approval from US FDA for Turqoz

Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)


Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries
News | August 01, 2023

Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries

The company has secured 506 marketing approvals for its oncology products across 76 countries.


Eugia Pharma receives USFDA approval for Plerixafor Injection
Drug Approval | July 26, 2023

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023


InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China
News | July 26, 2023

InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China

Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes